Monterey, CA , May 27, 2025 (GLOBE NEWSWIRE) -- ChampionsGate Acquisition Corporation (Nasdaq: CHPGU) (the “Company”) announced today the pricing of its initial public offering of 6,500,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “CHPGU” beginning May 28, 2025. Each unit consists of one Class A ordinary share and one right to receive one-eighth of one Class A ordinary share. Once the securities comprising the unit ...

Core Points - Fast Track Group has successfully closed its initial public offering (IPO) of 3,750,000 ordinary shares at a price of $4.00 per share, raising approximately $15 million in gross proceeds [1] - The company's shares began trading on the Nasdaq Capital Market under the symbol "FTRK" on May 23, 2025 [1] - The underwriters have a 45-day option to purchase an additional 562,500 ordinary shares to cover over-allotments [2] Company Overview - Fast Track Group is a leading entertainment-focused event management and celebrity agency company, established in Singapore in 2012 [6] - The company has expanded its operations across the Asia Pacific region, gaining a reputation as a preferred partner for event and endorsement organizers [6] - Fast Track Group offers a range of value-added services, including media planning, PR management, technical production planning, celebrity sourcing, and event manpower support [6] Offering Details - The IPO was conducted under the company's registration statement on Form F-1, which was filed with the U.S. Securities and Exchange Commission (SEC) [4] - The final prospectus related to the offering has been filed with the SEC and is available on the SEC's website [4]

Core Points - Pelican Acquisition Corporation has priced its initial public offering (IPO) of 7,500,000 units at $10.00 per unit, with trading commencing on May 23, 2025 [1] - Each unit consists of one ordinary share and one right, with each right entitling the holder to receive one-tenth of an ordinary share upon the completion of a business combination [1] - The offering is expected to close on May 27, 2025, subject to customary closing conditions [3] Company Overview - Pelican Acquisition Corporation is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [6] - The company's search for a prospective target business is not limited to a specific industry or geographic region [6] Underwriting and Regulatory Information - EarlyBirdCapital, Inc. is the sole book-running manager, while IB Capital LLC is acting as co-manager and qualified independent underwriter [3] - The underwriters have a 45-day option to purchase an additional 1,125,000 units to cover over-allotments [3] - A registration statement for these securities was declared effective by the Securities and Exchange Commission on May 22, 2025 [4]

Company Overview - Cal Redwood Acquisition Corp. announced the pricing of its initial public offering (IPO) of 20,000,000 units at a price of $10.00 per unit, with trading expected to begin on May 23, 2025 [1] - Each unit consists of one Class A ordinary share and one right to receive one tenth of a Class A ordinary share upon the consummation of an initial business combination [1] - The offering is expected to close on May 27, 2025, subject to customary closing conditions [1] Business Focus - The Company was formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] - While the Company may pursue opportunities in any industry, it expects to focus on the technology, media, and telecommunications (TMT) sector, as well as sectors undergoing technology disruption [2] Underwriting and Additional Units - Cohen & Company Capital Markets is acting as the lead book-running manager, with Seaport Global Securities as the joint book-runner [3] - The Company has granted underwriters a 45-day option to purchase up to 3,000,000 additional units at the IPO price to cover over-allotments [3]

NEW YORK, May 20, 2025 /PRNewswire/ -- ProCap Acquisition Corp (the "Company") announced today the pricing of its upsized initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC ("Nasdaq") and begin trading tomorrow, May 21, 2025, under the ticker symbol "PCAPU." Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Cla ...

Company Overview - Columbus Circle Capital Corp. I is a blank check company formed to effect mergers, amalgamations, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses [7] - The management team includes Gary Quin as CEO and Chairman, and Joseph W. Pooler, Jr. as CFO, along with independent directors Garrett Curran, Alberto Alsina Gonzalez, Dr. Adam Back, and Matthew Murphy [7] Initial Public Offering (IPO) Details - The company closed its upsized initial public offering of 25,000,000 units, with gross proceeds of $250,000,000, priced at $10.00 per unit [1] - The offering included 3,000,000 units from the partial exercise of the underwriters' overallotment option [1] - Units began trading on NASDAQ under the ticker symbol "CCCMU" on May 16, 2025, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant [2] Financial and Legal Aspects - The proceeds from the IPO and a simultaneous private placement were placed in the company's trust account for the benefit of public shareholders [6] - The registration statement for the offering was declared effective by the SEC on May 15, 2025 [4] - Legal counsel for the company included Ellenoff Grossman & Schole LLP and Ogier (Cayman) LLP, while Loeb & Loeb LLP served as legal counsel to the underwriters [3] Cohen & Company Overview - Cohen & Company Inc. is a financial services company specializing in capital markets and asset management services [8] - The company operates through segments including Capital Markets, Asset Management, and Principal Investing, with a focus on mergers and acquisitions, capital markets, and SPAC advisory services [8] - As of March 31, 2025, Cohen & Company had approximately $2.3 billion in assets under management, primarily in fixed income assets [9]

Core Viewpoint - MasterBeef Group has successfully issued an additional 155,000 ordinary shares at a price of US$4.00 per share, raising approximately $620,000 to support its expansion and operational initiatives [1] Group 1: Company Overview - MasterBeef Group is a full-service restaurant group based in Hong Kong, specializing in Taiwanese hotpot and Taiwanese barbecue [5] - The company operates 12 restaurant outlets under the Master Beef and Anping Grill brands through its Hong Kong Operating Subsidiaries [5] Group 2: Financial Details - The additional shares were issued as part of the partial exercise of the underwriter's over-allotment option related to the company's initial public offering [1] - The ordinary shares began trading on the Nasdaq Capital Market on April 10, 2025, under the ticker symbol "MB" [1] Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for: - Expansion of the restaurant network, including new outlets and franchising in Hong Kong and Southeast Asia [1] - Marketing and branding campaigns to enhance customer base and brand strength [1] - Production and sale of semi-finished food products, such as packaged hotpot soup base and marinated food products [1] - Investment in technology solutions for table service, inventory management, and order processing, along with IT system upgrades [1] - General corporate purposes to support business development and strategic direction [1]

Group 1 - The Company, Columbus Circle Capital Corp I, has announced the pricing of its upsized initial public offering (IPO) of 22,000,000 units at a price of $10.00 per unit, with trading expected to begin on May 16, 2025 [1] - Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant allowing the purchase of one Class A ordinary share at a price of $11.50 per share [1] - The Company has granted underwriters a 45-day option to purchase an additional 3,300,000 units at the IPO price to cover over-allotments [1] Group 2 - The Company is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] - The management team is led by Gary Quin as CEO and Chairman, and Joseph W. Pooler, Jr. as CFO, with independent directors including Garrett Curran, Alberto Alsina Gonzalez, Dr. Adam Back, and Matthew Murphy [2] Group 3 - Cohen & Company Capital Markets acted as the lead book-running manager for the offering, with Clear Street LLC as joint book-runner [3] - Legal counsel for the Company includes Ellenoff Grossman & Schole LLP and Ogier (Cayman) LLP, while Loeb & Loeb LLP served as legal counsel to the underwriters [3] Group 4 - A registration statement for the units and underlying securities was declared effective by the Securities and Exchange Commission on May 15, 2025 [4]

Core Viewpoint - Antalpha Platform Holding Company has announced the pricing of its initial public offering (IPO) of 3,850,000 ordinary shares at $12.80 per share, with trading expected to begin on Nasdaq under the ticker symbol "ANTA" on May 14, 2025 [1] Group 1: IPO Details - The offering includes a 30-day option for underwriters to purchase an additional 577,500 ordinary shares to cover over-allotments [2] - Antalpha expects to receive gross proceeds of approximately $49.3 million from the offering, which could increase to approximately $56.7 million if the over-allotment option is fully exercised [3] - The offering is set to close on May 15, 2025, subject to customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including investment in product development, sales and marketing, technology infrastructure, capital expenditure, global expansion, and other administrative matters [3] - The company plans to allocate funds for loan operations and customer funding advances to enhance fund flow and customer experience [3] - Antalpha also intends to invest in technologies, solutions, or businesses that complement its operations, as well as in Bitcoin and gold in digital form as part of its treasury management [3] Group 3: Company Background - Antalpha is a leading crypto fintech company focused on providing liquidity and risk management solutions to institutional Bitcoin miners [7] - The company serves as the primary lending partner of Bitmain, offering supply chain and margin loans through its Antalpha Prime technology platform [7]

Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million to fund clinical trials and other operational needs [1][3]. Group 1: Initial Public Offering Details - The company closed its initial public offering of 3,375,000 shares at a price of $4.00 per share, with trading commencing on May 9, 2025 [1]. - Gross proceeds from the offering amounted to $13.5 million before expenses [1]. - Underwriters were granted a 45-day option to purchase an additional 506,250 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a Phase III clinical trial for knee osteoarthritis [3]. - The company plans to initiate at least one non-registered corporate sponsorship study in multiple sclerosis [3]. - Proceeds will also be allocated for manufacturing its product candidate and general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin with potential therapeutic effects [6]. - The product is being developed as a treatment for knee pain in osteoarthritis patients who do not respond adequately to conventional therapies [6].